Inclusion Criteria:

        Only the patients meeting all the following criteria can be eligible to participate in the
        trial:

          1. Histologically and/or cytologically confirmed stage IV non-small cell lung cancer and
             ALK fusion

          2. At least one measurable lesion 3 No history of any systemic anti-tumor therapy.

        4. Agreement on providing formalin fixed tumor tissue specimen or fresh biopsy tissue from
        tumor lesions after diagnosis of metastasis 6. Age of 18-75 years 7. ECOG Scores 0-1; 8.
        Expected survival ≥ 3 months;

        Exclusion Criteria:

          1. Known allergy to recombinant humanized anti-PD-1 monoclonal antibody drug and its
             components;

          2. Histologically or cytopathologically confirmed combination with small cell lung cancer
             component or sarcomatoid lesion;

          3. Current participation in and receiving other study treatment, or participation in
             treatment of one study drug within 4 weeks prior to administration of JS001;

          4. Previous use of systematic chemotherapy for advanced NSCLC; targeted therapy for
             advanced NSCLC

          5. Previous use of anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or
             anti-CTLA-4 antibody (or any other antibody acting on T cells synergetic stimulation
             or checkpoint pathway, such as IDO, IL-2R, GITR);

          6. Chest (lung) radiotherapy > 30 Gy within 6 months prior to the start of study
             treatment.

          7. Active tuberculosis (TB), receiving anti-tuberculosis therapy currently or within one
             year prior to screening;

          8. Known active central nervous system (CNS) metastasis and/or cancerous meningitis;

          9. Spinal cord compression for which operation and/or radical radiotherapy has not been
             given, or no clinical evidence of stable disease for ≥4 weeks prior to enrollment
             after treatment for previously diagnosed spinal cord compression

         10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
             drainage

         11. Uncontrollable or symptomatic hypercalcemia

         12. Clinically uncontrolled active infection, including but not limited to acute
             pneumonia;

         13. Uncontrollable major epileptic seizure or superior vena cava syndrome

         14. Previous or current combination with other malignancies ;

         15. History of idiopathic pulmonary fibrosis, organized pneumonia (e.g., obliterating
             bronchiolitis), drug induced pneumonia, idiopathic pneumonia or evidence of active
             pneumonia during chest CT scanning for screening;

         16. Known hepatic diseases of clinical significance, including active viral hepatitis,
             alcoholic hepatitis or other hepatitis, liver cirrhosis, fatty liver, hereditary liver
             disease;

         17. Use of systemic immunosuppressive therapy for any active autoimmune disease within two
             years prior to Day 1 of the 1st cycle;

         18. Vaccination of live-virus vaccine within 30 days after the start of planned treatment